{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:44:42Z","timestamp":1783633482624,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Health Sciences of the National Institute of Biomedical Innovation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00262-020-02509-8","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T06:16:20Z","timestamp":1581401780000},"page":"1131-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I\/IIa clinical study"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0436-4296","authenticated-orcid":false,"given":"Eiji","family":"Kiyohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-8474","authenticated-orcid":false,"given":"Atsushi","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Yokomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Myoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2509_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0076-6879(93)21005-S","volume":"221","author":"Y Okada","year":"1993","unstructured":"Okada Y (1993) Sendai virus-induced cell fusion. Methods Enzymol 221:18\u201341","journal-title":"Methods Enzymol"},{"key":"2509_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1006\/mthe.2002.0647","volume":"6","author":"Y Kaneda","year":"2002","unstructured":"Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H (2002) Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6:219\u2013226","journal-title":"Mol Ther"},{"key":"2509_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2007.12.008","volume":"332","author":"Y Kondo","year":"2008","unstructured":"Kondo Y, Fushikida K, Fujieda T, Sakai K, Miyata K, Kato F, Kato M (2008) Efficient delivery of antibody into living cells using a novel HVJ envelope vector system. J Immunol Methods 332:10\u201317. https:\/\/doi.org\/10.1016\/j.jim.2007.12.008","journal-title":"J Immunol Methods"},{"key":"2509_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-06-1615","volume":"67","author":"M Kurooka","year":"2007","unstructured":"Kurooka M, Kaneda Y (2007) Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67:227\u2013236. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1615","journal-title":"Cancer Res"},{"key":"2509_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-007-0351-y","volume":"57","author":"A Fujihara","year":"2008","unstructured":"Fujihara A, Kurooka M, Miki T, Kaneda Y (2008) Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 57:73\u201384. https:\/\/doi.org\/10.1007\/s00262-007-0351-y","journal-title":"Cancer Immunol Immunother"},{"key":"2509_CR6","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/ijc.24234","volume":"124","author":"Y Kawaguchi","year":"2009","unstructured":"Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124:2478\u20132487. https:\/\/doi.org\/10.1002\/ijc.24234","journal-title":"Int J Cancer"},{"key":"2509_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11060-010-0355-x","volume":"103","author":"M Matsuda","year":"2011","unstructured":"Matsuda M, Nimura K, Shimbo T, Hamasaki T, Yamamoto T, Matsumura A, Kaneda Y (2011) Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J Neurooncol 103:19\u201331. https:\/\/doi.org\/10.1007\/s11060-010-0355-x","journal-title":"J Neurooncol"},{"key":"2509_CR8","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1158\/1078-0432.CCR-12-1595","volume":"18","author":"T Matsushima-Miyagi","year":"2012","unstructured":"Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y (2012) TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I\/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18:6271\u20136283. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1595","journal-title":"Clin Cancer Res"},{"key":"2509_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"2509_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"2509_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133. https:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"},{"key":"2509_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","volume":"180","author":"DL Morton","year":"1974","unstructured":"Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:635\u2013643","journal-title":"Ann Surg"},{"key":"2509_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/mt.2011.132","volume":"19","author":"TH Hwang","year":"2011","unstructured":"Hwang TH, Moon A, Burke J et al (2011) A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 19:1913\u20131922. https:\/\/doi.org\/10.1038\/mt.2011.132","journal-title":"Mol Ther"},{"key":"2509_CR14","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1172\/JCI24624","volume":"115","author":"HL Kaufman","year":"2005","unstructured":"Kaufman HL, Deraffele G, Mitcham J et al (2005) Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Investig 115:1903\u20131912. https:\/\/doi.org\/10.1172\/JCI24624","journal-title":"J Clin Investig"},{"key":"2509_CR15","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763\u20135771. https:\/\/doi.org\/10.1200\/JCO.2009.24.3675","journal-title":"J Clin Oncol"},{"key":"2509_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/gt.2011.123","volume":"19","author":"E Kiyohara","year":"2012","unstructured":"Kiyohara E, Tamai K, Katayama I, Kaneda Y (2012) The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 19:734\u2013741. https:\/\/doi.org\/10.1038\/gt.2011.123","journal-title":"Gene Ther"},{"key":"2509_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/cgt.2013.61","volume":"20","author":"A Tanemura","year":"2013","unstructured":"Tanemura A, Kiyohara E, Katayama I, Kaneda Y (2013) Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. Cancer Gene Ther 20:599\u2013605. https:\/\/doi.org\/10.1038\/cgt.2013.61","journal-title":"Cancer Gene Ther"},{"key":"2509_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2509_CR19","volume-title":"Clinical trials in oncology","author":"S Green","year":"2002","unstructured":"Green S, Benedetti J, Crowley J (2002) Clinical trials in oncology, 2nd edn. CRC Press, UK","edition":"2"},{"key":"2509_CR20","doi-asserted-by":"publisher","DOI":"10.5772\/55014","author":"T Nakajima","year":"2013","unstructured":"Nakajima T, Itai T, Wada H, Yamauchi T, Kiyohara E, Kaneda Y (2013) A novel therapy for melanoma and prostate cancer using a non-replicating Sendai virus particle (HVJ-E). IntechOpen. https:\/\/doi.org\/10.5772\/55014","journal-title":"IntechOpen"},{"key":"2509_CR21","unstructured":"National Cancer Institute NIoH, US Department of Health and Human Services (2008) Common terminology criteria for adverse events (CTCAE), ver 4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"},{"key":"2509_CR22","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ et al (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:6737\u20136747. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0759","journal-title":"Clin Cancer Res"},{"key":"2509_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1944-0","volume":"66","author":"B Weide","year":"2017","unstructured":"Weide B, Martens A, Wistuba-Hamprecht K et al (2017) Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. Cancer Immunol Immunother 66:441\u2013449. https:\/\/doi.org\/10.1007\/s00262-016-1944-0","journal-title":"Cancer Immunol Immunother"},{"key":"2509_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/14728222.2013.765407","volume":"17","author":"T Seya","year":"2013","unstructured":"Seya T, Azuma M, Matsumoto M (2013) Targeting TLR3 with no RIG-I\/MDA5 activation is effective in immunotherapy for cancer. Expert Opin Ther Targets 17:533\u2013544. https:\/\/doi.org\/10.1517\/14728222.2013.765407","journal-title":"Expert Opin Ther Targets"},{"key":"2509_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/cgt.2017.15","volume":"24","author":"K Fujita","year":"2017","unstructured":"Fujita K, Nakai Y, Kawashima A et al (2017) Phase I\/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. Cancer Gene Ther 24:277\u2013281. https:\/\/doi.org\/10.1038\/cgt.2017.15","journal-title":"Cancer Gene Ther"},{"key":"2509_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","volume":"64","author":"R Danielli","year":"2015","unstructured":"Danielli R, Patuzzo R, Di Giacomo AM et al (2015) Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother 64:999\u20131009. https:\/\/doi.org\/10.1007\/s00262-015-1704-6","journal-title":"Cancer Immunol Immunother"},{"key":"2509_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","volume":"18","author":"JF Thompson","year":"2008","unstructured":"Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18:405\u2013411. https:\/\/doi.org\/10.1097\/CMR.0b013e32831328c7","journal-title":"Melanoma Res"},{"key":"2509_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718\u2013730. https:\/\/doi.org\/10.1245\/s10434-009-0809-6","journal-title":"Ann Surg Oncol"},{"key":"2509_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdp325","volume":"21","author":"P Quaglino","year":"2010","unstructured":"Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG (2010) Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 21:409\u2013414. https:\/\/doi.org\/10.1093\/annonc\/mdp325","journal-title":"Ann Oncol"},{"key":"2509_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","volume":"13","author":"C Rozera","year":"2015","unstructured":"Rozera C, Cappellini GA, D'Agostino G et al (2015) Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med 13:139. https:\/\/doi.org\/10.1186\/s12967-015-0473-5","journal-title":"J Transl Med"},{"key":"2509_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","volume":"4","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Amatruda T, Reid T et al (2016) Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer 4:12. https:\/\/doi.org\/10.1186\/s40425-016-0116-2","journal-title":"J Immunother Cancer"},{"key":"2509_CR32","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D et al (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34:2619\u20132626. https:\/\/doi.org\/10.1200\/JCO.2016.67.1529","journal-title":"J Clin Oncol"},{"issue":"1109\u20131119","key":"2509_CR33","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(1109\u20131119):e1110. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027","journal-title":"Cell"},{"key":"2509_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T07:09:11Z","timestamp":1612940951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02509-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Toshihiro Nakajima is the employee of GenomIdea, Inc. Toshihiro Nakajima and Yasufumi Kaneda are stock-holders (0.08 and 0.5%) of GenomIdea, Inc. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed with the approval of the ethics committee at Osaka University Hospital (No. 746 on July 28th 2009). The project was allocated at the Medical Center for Translational Research with number MM0901. All procedures involving human participants were carried out in accordance with the ethical standards of the Osaka University Hospital, national research committee (the University Hospital Medical Information Network-UMIN000002376 and UMIN000012943) and in line with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Written informed consent for protocol therapy, analysis of patient samples, and use of data for research and publication were obtained from all individual participants prior to treatment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The wild-type HVJ (Z strain) was produced using HEK293 cells, which were purchased from the Japanese Collection of Research Bioresources Cell Bank (JCRB9068, Japan) and cloned as a GenomIdea Clone 20 (GIC20) to prepare the master cell bank for manufacture. Isozyme analysis was performed for authenticating the cell line. Four types of isozymes (lactate dehydrogenase, glucose-6-phosphate dehydrogenase, malate dehydrogenase, and nucleoside phosphorylase) of the master cell bank were analyzed for the identification and characterization of the cell line in GLP study at BioReliance (Stirling, Scotland).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}